HER3 as a Therapeutic Target in Cancer.

Karachaliou, Niki; Lazzari, Chiara; Verlicchi, Alberto; Sosa, Aaron E; Rosell, Rafael

Karachaliou, Niki; Lazzari, Chiara; Verlicchi, Alberto; Sosa, Aaron E; Rosell, Rafael.

Affiliation

Karachaliou N; Medical Oncology Department, Institute of Oncology Rosell (IOR), University Hospital Sagrat Cor, C/Viladomat 288, 08029, Barcelona, Spain. nkarachaliou@oncorosell.com.
Lazzari C; Departmemt of Oncology, Division of Experimental Medicine, IRCCS San Raffaele Hospital, Milan, Italy.
Verlicchi A; Ospedale Santa Maria delle Croci, Ravenna, Italy.
Sosa AE; Medical Oncology Department, Institute of Oncology Rosell (IOR), University Hospital Sagrat Cor, C/Viladomat 288, 08029, Barcelona, Spain.
Rosell R; Germans Trias i Pujol Research Institute, Badalona, Spain.

BioDrugs ; 31(1): 63-73, 2017 Feb.

Article in En | MEDLINE | ID: mdl-28000159

Subject(s)

Antineoplastic Agents/administration & dosage; Drug Delivery Systems/methods; Lung Neoplasms/drug therapy; Receptor, ErbB-3/antagonists & inhibitors; Animals; Cell Line, Tumor; Drug Resistance, Neoplasm/drug effects; Drug Resistance, Neoplasm/physiology; Humans; Lung Neoplasms/metabolism; Receptor, ErbB-3/metabolism

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Delivery Systems / Receptor, ErbB-3 / Lung Neoplasms / Antineoplastic Agents Limits: Animals / Humans Language: En Journal: BioDrugs Journal subject: ALERGIA E IMUNOLOGIA / GENETICA MEDICA / TERAPEUTICA / TERAPIA POR MEDICAMENTOS Year: 2017 Document type: Article Affiliation country: Spain

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google